David Adams
#176,640
Most Influential Person Now
Researcher
David Adams's AcademicInfluence.com Rankings
David Adamscomputer-science Degrees
Computer Science
#10971
World Rank
#11573
Historical Rank
Artificial Intelligence
#5397
World Rank
#5471
Historical Rank
Database
#7999
World Rank
#8333
Historical Rank
Download Badge
Computer Science
David Adams's Degrees
- PhD Computer Science Stanford University
Similar Degrees You Can Earn
Why Is David Adams Influential?
(Suggest an Edit or Addition)David Adams's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis (2018) (1423)
- Safety and efficacy of RNAi therapy for transthyretin amyloidosis. (2013) (782)
- Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders (2010) (782)
- Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis (2018) (553)
- Clinicopathologic findings and prognosis of chronic inflammatory demyelinating polyneuropathy (1999) (262)
- The course and prognostic factors of familial amyloid polyneuropathy after liver transplantation. (2000) (244)
- Familial amyloid polyneuropathy (2017) (228)
- Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study (2015) (228)
- Diagnostic pitfalls in sporadic transthyretin familial amyloid polyneuropathy (TTR-FAP) (2007) (215)
- Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease (2019) (207)
- Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis: Analysis of the APOLLO Study (2019) (206)
- Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: where are we now? A European network approach to defining the epidemiology and management patterns for TTR-FAP (2016) (182)
- Multifocal motor neuropathy with conduction block: a study of 24 patients. (1995) (179)
- Evolving landscape in the management of transthyretin amyloidosis (2015) (173)
- Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy. (2009) (166)
- Hereditary systemic amyloidosis due to Asp76Asn variant β2-microglobulin. (2012) (162)
- First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy (2016) (160)
- Genotype–phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France (2015) (133)
- Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy (2017) (130)
- Etifoxine improves peripheral nerve regeneration and functional recovery (2008) (128)
- Inflammatory vasculopathy in multifocal diabetic neuropathy. (2003) (121)
- From immunosuppression to tolerance. (2015) (119)
- Genetic study of transthyretin amyloid neuropathies: carrier risks among French and Portuguese families (2003) (115)
- Genotypic-phenotypic variations in a series of 65 patients with familial amyloid polyneuropathy (1998) (111)
- Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy (2020) (109)
- Effect on disability and safety of Tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy (2013) (106)
- Hereditary and acquired amyloid neuropathies (2001) (104)
- [Autonomic peripheral neuropathy]. (2012) (96)
- Contribution of nerve biopsy findings to the diagnosis of disabling neuropathy in the elderly. A retrospective review of 100 consecutive patients. (1996) (95)
- Rapid progression of familial amyloidotic polyneuropathy (2015) (94)
- Predictive value of anti-GM1 ganglioside antibodies in neuromuscular diseases: a study of 180 sera (1991) (92)
- Recommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis (2016) (78)
- Recent advances in the treatment of familial amyloid polyneuropathy (2013) (76)
- Cardiac sympathetic denervation in familial amyloid polyneuropathy assessed by iodine-123 metaiodobenzylguanidine scintigraphy and heart rate variability (1999) (76)
- Spectrum and prognosis of neurologic complications after hematopoietic transplantation (2006) (74)
- Prophylactic pacemaker implantation in familial amyloid polyneuropathy. (2012) (74)
- Regional difference and similarity of familial amyloidosis with polyneuropathy in France (2012) (72)
- Impact of Liver Transplantation on Cardiac Autonomic Denervation in Familial Amyloid Polyneuropathy (2006) (71)
- Painful proximal diabetic neuropathy: Inflammatory nerve lesions and spontaneous favorable outcome (1997) (70)
- Axonal Regeneration and Neuroinflammation: Roles for the Translocator Protein 18 kDa (2012) (68)
- Domino liver transplants for metabolic disorders: experience with familial amyloidotic polyneuropathy (1999) (68)
- FAP Neuropathy and Emerging Treatments (2014) (65)
- Acute myeloradiculitis due to cytomegalovirus as the initial manifestation of AIDS. (1989) (64)
- Transthyretin amyloid polyneuropathies mimicking a demyelinating polyneuropathy (2018) (61)
- Association of Patisiran, an RNA Interference Therapeutic, With Regional Left Ventricular Myocardial Strain in Hereditary Transthyretin Amyloidosis: The APOLLO Study. (2019) (58)
- Hereditary and inflammatory neuropathies: a review of reported associations, mimics and misdiagnoses (2016) (57)
- Domino liver transplants for metabolic disorders: experience with familial amyloidotic polyneuropathy. (1999) (56)
- Monoclonal gammopathy and neuropathy (2007) (55)
- TTR kinetic stabilizers and TTR gene silencing: a new era in therapy for familial amyloidotic polyneuropathies (2016) (52)
- Contribution of plexus MRI in the diagnosis of atypical chronic inflammatory demyelinating polyneuropathies (2016) (50)
- Potential Role of In Vivo Confocal Microscopy for Imaging Corneal Nerves in Transthyretin Familial Amyloid Polyneuropathy. (2016) (50)
- Transthyretin gene analysis in European patients with suspected familial amyloid polyneuropathy. (1995) (50)
- A brief compound test for assessment of autonomic and sensory-motor dysfunction in familial amyloid polyneuropathy (2007) (50)
- Transthyretin gene analysis in European patients with suspected familial amyloid polyneuropathy (1996) (50)
- Myocardial Muscarinic Receptor Upregulation and Normal Response to Isoproterenol in Denervated Hearts by Familial Amyloid Polyneuropathy (2001) (43)
- Symptomatic and proven de novo amyloid polyneuropathy in familial amyloid polyneuropathy domino liver recipients (2011) (40)
- Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner (2020) (39)
- Changes in renal function in patients with familial amyloid polyneuropathy treated with orthotopic liver transplantation. (2004) (38)
- Cardiac Dysautonomia Predicts Long-Term Survival in Hereditary Transthyretin Amyloidosis After Liver Transplantation. (2016) (37)
- Motor conduction block and high titres of anti-GM1 ganglioside antibodies: pathological evidence of a motor neuropathy in a patient with lower motor neuron syndrome. (1993) (37)
- Early data on long‐term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2‐year update from the open‐label extension of the NEURO‐TTR trial (2020) (34)
- Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis (2020) (34)
- Angiographic Signatures of the Predominant Form of Familial Transthyretin Amyloidosis (Val30Met Mutation). (2018) (34)
- An amyotrophic lateral sclerosis-like syndrome revealing an amyloid polyneuropathy associated with a novel transthyretin mutation (2013) (33)
- Long-term Course of Demyelinating Neuropathies Occurring During Tumor Necrosis Factor-– Blocker Therapy (2009) (28)
- Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial (2022) (28)
- Ultrastructural characterisation of the M protein in nerve biopsy of patients with POEMS syndrome (1998) (27)
- Short-term evolution of spinal cord damage in multiple sclerosis: a diffusion tensor MRI study (2012) (27)
- Cardiac denervation evidenced by MIBG occurs earlier than amyloid deposits detection by diphosphonate scintigraphy in TTR mutation carriers (2018) (27)
- Immunological Hallmarks of JC Virus Replication in Multiple Sclerosis Patients on Long-Term Natalizumab Therapy (2013) (26)
- Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis (2019) (26)
- Varied patterns of inaugural light-chain (AL) amyloid polyneuropathy: a monocentric study of 24 patients (2011) (26)
- A small deep infarct revealing leukoencephalopathy, calcifications and cysts in an adult patient (2008) (24)
- Multifocal neuropathy due to plasma cell infiltration of peripheral nerves in multiple myeloma (2006) (24)
- Varicella-zoster virus acute myelitis in a patient with MS treated with natalizumab (2013) (23)
- Current and future treatment of amyloid neuropathies (2014) (23)
- Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis (2022) (21)
- Transthyretin gene mutations in British and French patients with amyloid neuropathy. (1993) (21)
- Prediction of long-term survival after liver transplantation for familial transthyretin amyloidosis. (2015) (20)
- Neuropathies motrices multifocales avec blocs de conduction: 39 cas (1997) (20)
- Upper limb onset of hereditary transthyretin amyloidosis is common in non‐endemic areas (2018) (20)
- Amyloid neuropathies. (2012) (19)
- Reversibility of Acquired Amyloid Polyneuropathy After Liver Retransplantation (2013) (19)
- Treating PMP22 gene duplication-related Charcot-Marie-Tooth disease: The past, the present and the future. (2020) (19)
- Haplotype analysis of French, British and other European patients with familial amyloid polyneuropathy (met 30 and tyr 77) (1995) (19)
- Multifocal deficits due to leukemic meningoradiculitis in chronic lymphocytic leukemia (2009) (18)
- Familial amyloid polyneuropathy: When does it stop to be asymptomatic and need a treatment? (2016) (18)
- Diagnostic usefulness of plexus magnetic resonance imaging in chronic inflammatory demyelinating polyradiculopathy without electrodiagnostic criteria of demyelination (2018) (18)
- Aphasia in border‐zone infarcts has a specific initial pattern and good long‐term prognosis (2011) (18)
- Charcot–Marie–Tooth disease misdiagnosed as chronic inflammatory demyelinating polyradiculoneuropathy: An international multicentric retrospective study (2021) (16)
- A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis (2020) (16)
- Safety of intravenous immunoglobulin in the elderly treated for a dysimmune neuromuscular disease (2015) (15)
- Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey (2021) (14)
- Diffusion MRI and tensor tractography in ischemic optic neuropathy (2012) (14)
- [Ocular involvement in familial amyloid polyneuropathy]. (2013) (14)
- Ultrastructural immunolabelling of amyloid fibrils in acquired and hereditary amyloid neuropathies (2004) (14)
- Phase 1 study of ALN-TTRsc02, a subcutaneously administered investigational RNAi therapeutic for the treatment of transthyretin-mediated amyloidosis (2019) (14)
- Circadian rhythm of blood pressure reflects the severity of cardiac impairment in familial amyloid polyneuropathy. (2012) (14)
- Thrombolysis in Stroke Patients with Isolated Aphasia (2016) (12)
- New transthyretin variants SER 91 and SER 116 associated with familial amyloidotic polyneuropathy (1998) (12)
- PHASE 2 OPEN-LABEL EXTENSION (OLE) STUDY OF PATISIRAN, AN INVESTIGATIONAL RNA INTERFERENCE (RNAI) THERAPEUTIC FOR THE TREATMENT OF HEREDITARY ATTR AMYLOIDOSIS WITH POLYNEUROPATHY (2017) (12)
- Squalenoyl siRNA PMP22 nanoparticles are effective in treating mouse models of Charcot-Marie-Tooth disease type 1 A (2021) (12)
- Expert opinion on monitoring symptomatic hereditary transthyretin-mediated amyloidosis and assessment of disease progression (2021) (11)
- Cause of death analysis and temporal trends in survival after liver transplantation for transthyretin familial amyloid polyneuropathy (2018) (11)
- Is distal motor and/or sensory demyelination a distinctive feature of anti-MAG neuropathy? (2016) (11)
- PHASE 2 OPEN-LABEL EXTENSION STUDY OF PATISIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC FOR THE TREATMENT OF FAMILIAL AMYLOID POLYNEUROPATHY (2015) (11)
- Transcriptome Analysis of Peripheral Blood in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients Identifies TNFR1 and TLR Pathways in the IVIg Response (2016) (11)
- Motor neuron syndromes and monoclonal IgM antibodies to gangliosides. (1991) (11)
- Brentuximab vedotin treatment associated with acute and chronic inflammatory demyelinating polyradiculoneuropathies (2020) (11)
- [Multifocal motor neuropathies with conduction blocks. 39 cases]. (1997) (11)
- Optimizing the management of transthyretin familial amyloid polyneuropathy in Europe: early diagnosis and effective care (2016) (10)
- Acquired and inherited amyloidosis: Knowledge driving patients' care (2020) (10)
- Domino liver transplantation from familial amyloidotic polyneuropathy donors: how close is the damocles sword to the recipient? (2007) (10)
- Small fiber neuropathy in Sjögren syndrome: Comparison with other small fiber neuropathies (2020) (9)
- Comparison of Lewis–Sumner syndrome with chronic inflammatory demyelinating polyradiculoneuropathy patients in a tertiary care centre (2020) (9)
- Neurological complications induced by immune checkpoint inhibitors: a comprehensive descriptive case-series unravelling high risk of long-term sequelae (2021) (9)
- Conjunctival lymphangiectasia as a biomarker of severe systemic disease in Ser77Tyr hereditary transthyretin amyloidosis (2020) (9)
- Intracerebral Hemorrhage Caused by Thrombosis of Developmental Venous Anomaly: Total Recovery following Anticoagulation (2010) (9)
- Amyloidosis from the patient perspective: the French daily impact of amyloidosis study (2022) (8)
- Refractory T-Cell Anergy and Rapidly Fatal Progressive Multifocal Leukoencephalopathy After Prolonged CTLA4 Therapy (2017) (8)
- Preliminary assessment of neuropathy progression in patients with hereditary ATTR amyloidosis after orthotopic liver transplantation (OLT) (2015) (8)
- Hereditary transthyretin amyloidosis: current treatment (2020) (8)
- Patisiran treatment in patients with hereditary transthyretin‐mediated amyloidosis with polyneuropathy after liver transplantation (2022) (8)
- Characteristics of Patients with Late- vs. Early-Onset Val30Met Transthyretin Amyloidosis from the Transthyretin Amyloidosis Outcomes Survey (THAOS) (2021) (8)
- Vasculitis neuropathy mimicking lower limb mono-radiculopathy: a study and follow-up of 8 cases (2013) (7)
- [Demonstration of genetic mutation in most of the amyloid neuropathies with sporadic occurrence]. (1992) (7)
- Advances in the treatment of chronic inflammatory demyelinating neuropathies in 2010 (2011) (7)
- Gadolinium-enhanced MRI in central nervous system Behçet's disease (2004) (7)
- Skin amyloid deposits and nerve fiber loss as markers of neuropathy onset and progression in hereditary transthyretin amyloidosis (2022) (7)
- Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin-mediated (hATTR) amyloidosis : Results from the phase 3 APOLLO study (2018) (7)
- Patisiran, an Investigational RNAi Therapeutic for Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Polyneuropathy: Results from the Phase 3 APOLLO study (CT.001) (2018) (7)
- Multimodality Imaging of Cardiac Transthyretin Amyloidosis 16 Years After a Domino Liver Transplantation (2016) (7)
- Late‐onset familial amyloid polyneuropathy with the TTR Met 30 mutation in France (1993) (6)
- Cerebral infarction following subcutaneous immunoglobulin therapy for chronic inflammatory demyelinating polyradiculoneuropathy (2016) (6)
- [Treatment of familial amyloid polyneuropathy]. (2012) (6)
- Short and long-term effect of IVIg in demyelinating neuropathy associated with MGUS, experience of a monocentric study. (2011) (5)
- Oligonucleotide Drugs for Transthyretin Amyloidosis. (2018) (5)
- FAP in India: a first genetically proven case (2015) (5)
- ALN-TTR, an RNAI therapeutic for the treatment of transthyretin amyloidosis (2011) (5)
- Conjunctival lymphangiectasia: a novel ocular manifestation of hereditary transthyretin amyloidosis (2019) (5)
- Familial amyloid polyneuropathy: elaboration of a therapeutic patient education programme, “EdAmyl” (2014) (5)
- Somatostatin analogues for refractory diarrhoea in familial amyloid polyneuropathy (2018) (4)
- When to suspect transthyretin amyloidosis in cases of isolated vitreous opacities? (2020) (4)
- HELIOS-A: RESULTS FROM THE PHASE 3 STUDY OF VUTRISIRAN IN PATIENTS WITH HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS WITH POLYNEUROPATHY (2022) (4)
- P.186 Phase 2 open-label extension study of patisiran, an investigational siRNA agent for hereditary ATTR amyloidosis with polyneuropathy (hATTR-PN) (2016) (4)
- Phase 2 Open-Label Extension Study (OLE) of Patisiran, an Investigational RNAi Therapeutic for Familial Amyloid Polyneuropathy (FAP) (S38.003) (2016) (4)
- Hematopoietic stem cell transplantation in chronic inflammatory demyelinating polyneuropathy: French experience about four patients, under the behalf of French society for bone marrow transplantation (2021) (4)
- Specific postoperative complications of vitrectomy in hereditary transthyretin amyloidosis (2021) (4)
- HELIOS-A: 9-month results from the phase 3 study of vutrisiran in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy (2021) (3)
- Late and Fatal Deterioration of an Intracerebral Hemorrhage Attributable to the Onset of a High Titer of Acquired Factor V Inhibitor (2008) (3)
- P.024 Long-term use of patisiran in patients with hereditary transthyretin amyloidosis (hATTR): 12 month efficacy & safety data from a global open label extension (OLE) study (2019) (3)
- Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin-mediated (hATTR) Amyloidosis : Results from the phase 3 APOLLO study (2018) (3)
- Multifocal Neuropathy with Upper Limb Onset as a Frequent Phenotype in Familial Amyloid Polyneuropathy in France (P05.065) (2013) (3)
- [Review of the recent literature on peripheral neuropathies: therapeutic advances]. (2013) (3)
- Infusion related reactions in patients with hATTR amyloidosis treated with patisiran (2018) (2)
- Impact of Patisiran on overall health status in hATTR amyloidosis : Results from the APOLLO trial (2018) (2)
- Phase 2 open-label extention (OLE) study of patisiran, an investigational siRNA agent for familial amyloidotic polyneuropathy (FAP) (2015) (2)
- Vitreous amyloidosis with autonomic neuropathy of the digestive tract associated with a novel transthyretin p.Gly87Arg variant in a Bangladeshi patient: a case report (2017) (2)
- Burden of Illness for Patients with Hereditary Attr Amyloidosis with Polyneuropathy Begins with Symptom Onset and Increases with Disease Progression (2016) (2)
- Efficacy and Safety of Octagam® in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (2019) (2)
- [Hereditary amyloid neuropathies]. (1995) (2)
- Open Label Extension of the Phase 3 Study NEURO-TTR to Assess the Long-term Efficacy and Safety of Inotersen in Patients With Hereditary Transthyretin Amyloidosis (P1.324) (2018) (2)
- Evaluation of Quality of Life and Disability in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Polyneuropathy Following Treatment with Patisiran, An Investigational RNAi Therapeutic: Results from the Phase 3 APOLLO Study (S31.003) (2018) (2)
- Patients with hereditary ATTR amyloidosis experience an increasing burden of illness as the disease progresses (2015) (2)
- Outcomes of patients with hereditary transthyretin-mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a Phase 3 study of patisiran (2019) (2)
- Anti‐disialosyl‐immunoglobulin M chronic autoimmune neuropathies: a nationwide multicenter retrospective study (2022) (2)
- Therapeutic education programme in TTR-FAP (2015) (2)
- 1170Tafamidis versus liver transplantation as first-line therapy for hereditary transthyretin amyloidosis (2019) (2)
- Treating hereditary transthyretin amyloidosis: Present & future challenges. (2022) (2)
- Impact of baseline polyneuropathy severity on patisiran treatment outcomes in the APOLLO trial (2022) (2)
- Ocular manifestations of transthyretin-related familial amyloid polyneuropathy (2015) (2)
- Interim results from phase ii trial of aln-ttr02, a novel RNAi therapeutic for the treatment of familial amyloidotic polyneuropathy (2013) (2)
- Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year update (2022) (2)
- Global open-label extension: 24-month data of patisiran in patients with HATTR amyloidosis (2021) (1)
- Inotersen Improves Quality of Life and Neuropathy in Patients with Hereditary Transthyretin (HATTR) Amyloidosis with Polyneuropathy: Results of the Phase 3 Study Neuro-TTR (2018) (1)
- Retinal and choroidal vascular abnormalities in TTR-FAP (2015) (1)
- [Liver transplantation for familial amyloid polyneuropathy]. (2010) (1)
- 20 - Nonsystemic vasculitis neuropathy: initial presentation and long term follow-up in a monocentric series of 20 patients (2015) (1)
- Abstracts from the First European Meeting for ATTR Amyloidosis for Doctors and Patients (2017) (1)
- Neuropathy progression in patients with hATTR amyloidosis : Analysis of the APOLLO placebo arm (2018) (1)
- [Mixed histiocytosis, a rare cause of stroke]. (2015) (1)
- Liver transplantation in patients with familial amyloidotic polyneuropathy (FAP) : study in a cohort of 29 patients and long-term results in 10 patients (1998) (1)
- [Metabolic neuropathies]. (2008) (1)
- P011. Impact of Patisiran on Activities of Daily Living and Functional Status in hATTR Amyloidosis (2021) (1)
- Inflammatory demyelinating polyneuropathies and lymphoma: clues to diagnosis and therapy (2021) (1)
- First European Congress on Hereditary ATTR amyloidosis. (2015) (1)
- Long-term Safety and Efficacy of Patisiran in Patients with hATTR Amyloidosis : Global OLE Study (2020) (1)
- Burden of Hereditary Transthyretin Amyloidosis With Polyneuropathy in Patients Enrolled in the Phase 3 Study NEURO-TTR (P1.331) (2018) (1)
- Changes in neuropathy stage in patients with hATTR amyloidosis following patisiran treatment : Analysis from APOLLO (2018) (1)
- [New elements in the diagnosis and the treatment of primary AL amyloid polyneuropathy and neuropathy due to POEMS syndrome]. (2011) (1)
- Chlorambucil fails to improve patients with motor neuropathies and antibodies to gangliosides. (1992) (1)
- EFFECT OF PATISIRAN ON NERVE FIBER DENSITY AND AMYLOID CONTENT IN SKIN : RESULTS FROM PHASE 2 OPEN LABEL EXTENSION (OLE) STUDY IN HATTR AMYLOIDOSIS (2017) (1)
- Management of stage 1 TTR FAP: French experience (2015) (1)
- [Cervical spinal sarcoidosis mimicking compressive cervical myelopathy: Poor prognosis after surgery]. (2019) (1)
- Plasma proteome analysis of patients with hereditary transthyretin-mediated (hATTR) amyloidosis establishes neurofilament light chain (NfL) as a biomarker of disease and treatment response (2019) (1)
- Burden of Illness for Patients with familial amyloidotic Polyneuropathy (Fap) Begins Early and Increases with Disease Progression (2015) (1)
- NT-proBNP Levels in Patients with Hereditary Transthyretin-mediated Amyloidosis Treated in the Phase 3 APOLLO Study Based on Diuretic Use (2018) (0)
- Secondary glaucoma in familial amyloid polyneuropathy (2013) (0)
- Teachings from the French database of TTR familial amyloidotic polyneuropathy (TTR-FAP): large genetic and phenotypic heterogeneity, usefulness of TTR gene testing. (2015) (0)
- IDENTIFICATION OF TRANSTHYRETIN FAMILIAL AMYLOID POLYNEUROPATHY IN NEW COUNTRIES (2017) (0)
- siRNA Phase 2 Open-Label Extension Study for Treating Familial Amyloid Polyneuropathy (2015) (0)
- Stability of cardiac sympathetic denervation but progression of cardiomyopathy in familial amyloid polyneuropathy 2 years after liver transplantation (2005) (0)
- How a Drug is Assessed Once It ’ s in Clinical Trials : A Perspective from a Clinical Pharmacology Reviewer (2018) (0)
- PATISIRAN PH 2 OPEN-LABEL EXTENSION STUDY IN FAMILIAL AMYLOIDOTIC POLYNEUROPATHY (2016) (0)
- Renal involvement in amyloid polyneuropathy. Implications for pre-liver transplantation evaluation (1996) (0)
- 244 High incidence of AV block and prophylactic pacing in familial amyloid polyneuropathy (2011) (0)
- Oral Sessions (2010) (0)
- SAT0429 How phenotype of the small fibre neuropathy (SFN) in primary sjÖgren syndrome (PSS) differs from others causes of small fibre neuropathy? (2018) (0)
- A Tribute to the Editorial Board 2016 (2016) (0)
- Secondary Glaucoma in transthyretin (TTR)-related Familial Amyloid Polyneuropathy (2013) (0)
- Correction to: Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis (2020) (0)
- P17 - Clinical spectrum, causes and evolution of disabling neuropathies in patients with hematopoietic stem cell transplantation on a 20 years period (2015) (0)
- Inotersen Improves Norfolk Quality of Life-Diabetic Neuropathy Measures in Patients With Hereditary Transthyretin Amyloidosis with Polyneuropathy in the Phase 3 Study NEURO-TTR (S5.006) (2018) (0)
- Cardiac dysautonomia predicts long term survival in transthyretin amyloidosis (2017) (0)
- Early cardiac denervation in asymptomatic patients with familial amyloid polyneuropathy (2006) (0)
- Safety and Efficacy of Inotersen in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (NEURO-TTR) (N2.001) (2018) (0)
- Choroidal and retinal angiopathy in V30M hereditary transthyretin amyloidosis (2017) (0)
- Accommodative convergence pupillary eye system and psychological status of healthy school aged children (2018) (0)
- 247 Cardiac phenotype of familial amyloid polyneuropthy according to genotype (2010) (0)
- Corneal nerves as a biomarker of peripheral neuropathy : the example of transthyretin amyloidosis (2017) (0)
- LIVER TRANSPLANTATION (LT) IN TTR FAMILIAL AMYLOID POLYNEUROPATHY (FAP). THE PROGNOSIS IS RELATED TO THE TIMING FOR LT AND TO THE TYPE OF MUTATION. (2004) (0)
- Early detection of skin and cardiac amyloid deposits among asymptomatic carriers of hereditary pathogenic transthyretin mutation with normal electroneuromyography (2020) (0)
- [Sensory and motor peripheral neuropathy, high cerebrospinal fluid protein and monoclonal IgG immunoglobulins in a 38 year-old man]. (2000) (0)
- Cardiomyopathy and peripheral polyneuropathy severity in patients with Glu 89 Gln mutation at the time of diagnosis (2015) (0)
- Rejection and infection after liver transplantation (LT) for familial amyloid polyneuropathy (FAP) (1996) (0)
- French patients with amyloid neuropathy . Transthyretin gene mutations in British and (0)
- Brugada syndrome revealed by vertigo caused by cerebellar infarction (2010) (0)
- The rehabilitation in the management of Transthyretin Familial Amyloid Polyneuropathy (2015) (0)
- 07 - Transcriptome analysis identifies TNFR1 and TLRs pathways in the IVIg response in chronic inflammatory demyelinating polyneuropathies (2015) (0)
- Neuropathic phenotypes and natural history of FAP (2015) (0)
- MRI for the detection of Restrictive Cardiomyopathy in Familial Amyloid Polyneuropathy (2005) (0)
- Domino liver transplantation: A french experience (2003) (0)
- Abstract 14674: Cardiac Infiltration is an Independent Risk Factor of Poor Survival after Liver Transplantation in Transthyretin Amyloidosis (2012) (0)
- Evaluation of liver transplantation in familial amyloid polyneuropathy (1996) (0)
- Long term effect of liver transplantation (LT) on met 30 TTR familial amyloid polyneuropathy (FAP) (2003) (0)
- 260 Dipping pattern on 24h ambulatory blood pressure monitoring (ABPM) is related to cardiac infiltration in cardiac amyloidosis (2012) (0)
- Similar diagnostic value of HMPD and DPD for the detection of cardiac involvement in TTR-familial amyloid neuropathy (2013) (0)
- Antisense therapies in neurological diseases. (2021) (0)
- Squalenoyl siRNA PMP22 nanoparticles are effective in treating mouse models of Charcot-Marie-Tooth disease type 1 A (2021) (0)
- Pathological spectrum of hereditary transthyretin renal amyloidosis and clinicopathologic correlation: a French observational study. (2023) (0)
- Phase 2 open-label extension study (ole) of patisiran, an investigational sIRNA investigational agent for familial amyloid polyneuropathy (fap) (2015) (0)
- [Familial amyloid polyneuropathies: therapeutic issues]. (2012) (0)
- Familial Amyloidosis with Polyneuropathy (FAP): Lessons from the French Model of Care in Last 5 Years from the National Referral Center (NNERF) and National Network for FAP (CORNAMYL) (P05.063) (2013) (0)
- Genotype–phenotype correlation in French patients with myelin protein zero gene‐related inherited neuropathy (2021) (0)
- [Use of RNAi in the treatment of hereditary amyloidosis due to mutation of transthyretin]. (2014) (0)
- Do combination of chemotherapy (CT) and radiotherapy (RT) modify the patterns of relapse and the late central nervous system toxicity (LCNST) in immunocompetent patients with primary cerebral non-hodgkin's lymphoma? (1999) (0)
- Comparison between tafamidis and liver transplantation as first-line therapy for hereditary transthyretin amyloidosis. (2023) (0)
- Acute myeloradiculitis duetocytomegalovirus asthe initial manifestation ofAIDS (1989) (0)
- Red Flags for Chronic Inflammatory Demyelinating Polyradiculoneuropathy Associated with Sarcoidosis or Connective Tissue Diseases (2023) (0)
- [Peripheral neuropathies during systemic diseases: Part II (vasculitis)]. (2023) (0)
- [Peripheral neuropathies during systemic diseases: Part I (connective tissue diseases and granulomatosis)]. (2023) (0)
- Neuropathie amyloïde à transthyrétine: du diagnostic au traitement1 (2023) (0)
- 234 Electrophysiological characteristics in cardiac amyloidosis due to familial amyloid polyneuropathy (2012) (0)
- Effects of Patisiran, an RNA Interference Therapeutic, on Regional Left Ventricular Myocardial Deformation in Hereditary Transthyretin Amyloidosis: The APOLLO Study (2019) (0)
- Effects of Patisiran, an RNA Interference Therapeutic, on Regional Left Ventricular Myocardial Deformation in Hereditary Transthyretin Amyloidosis: The APOLLO Study (2019) (0)
- Longitudinal changes in mNIS+7 are associated with changes in ambulatory status in hereditary transthyretin-mediated amyloidosis (2018) (0)
- Discussion à propos de la communication : « Neuropathie amyloïde à transthyrétine: du diagnostic au traitement »1 (2023) (0)
- Early detection of cardiac and skin amyloid deposits among asymptomatic carriers of hereditary pathogenic transthyretin mutation (2021) (0)
- P.025 APOLLO, a phase 3 study of patisiran for the treatment of hereditary transthyretin amyloidosis (hATTR): 18-month safety and efficacy in subgroup with cardiac involvement (2019) (0)
- Comparison of Efficacy Outcomes with Vutrisiran vs. Patisiran in hATTR Amyloidosis with Polyneuropathy: Post-hoc Analysis of the HELIOS-A Study (S14.003) (2023) (0)
- Neurofilament Light Chain (NfL) as a Potential Biomarker of Treatment Response in Hereditary TransthyretinMediated (hATTR) Amyloidosis: Patisiran Global OLE Study (2021) (0)
- P-48 Neurofilament light chain as a biomarker in hereditary transthyretin-mediated amyloidosis: 36-month data from the patisiran global open-label extension (2023) (0)
- EYS606 for the treatment of non‐infectious uveitis (NIU) (2018) (0)
- 103 Echocardiographic evaluation of left and right ventricular functions in familial amyloidosis polyneuropathy: preserved or not? (2010) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With David Adams?
David Adams is affiliated with the following schools:
